Abstract
<h3>Purpose</h3> Myocarditis is a common cause of pediatric heart failure and may require treatment with mechanical circulatory support (MCS). The purpose of this study is to describe the frequency of MCS use in pediatric myocarditis, types of MCS used, and outcomes of patients who receive MCS. <h3>Methods</h3> This study utilized the administrative Kids' Inpatient Database (KID), a nationally representative sample of discharge data. Five years of KID admissions (2003, 2006, 2009, 2012 and 2016) were queried using ICD-9/10 codes to identify those with a diagnosis of myocarditis. MCS strategies and outcomes were calculated and compared using logistic regression. <h3>Results</h3> Of 5,661 admissions for myocarditis, MCS was used in 194 (3.4%). ECMO was used in 82 (42.3%), a temporary ventricular assist device (tVAD) in 38 (19.6%), a durable VAD (dVAD) in 53 (27.3%) and combination MCS (cMCS) in 22 (11.3%). Half of admissions (n=2854, 50.4%), occurred in patients age 13-18 years, however teenagers were less likely than children <13 years to require MCS (2.7% vs 4.2%, p=0.008). Overall, 336 (5.9%) patients died and 94 (1.7%) patients underwent transplant. Mortality (22.3% vs 5.4%), stroke (16.4% vs 3.5%), significant bleeding (7.8% vs 1.1%), arrhythmia (49.7% vs 23.6%), and renal failure (35.3% vs 7.1%) were higher in patients treated with MCS (p<0.0001 for all). There was no significant difference in mortality between patients receiving dVAD, tVAD or cMCS when compared to ECMO. There was a significantly higher rate of transplant in patients who received any other MCS type compared to ECMO (p≤0.0005 for all). MCS use was associated with significantly longer admissions (28.2 vs 3.8 days, p<0.0001) and significantly higher charges (median $887,799 vs $57,157, p<0.0001). <h3>Conclusion</h3> MCS is used in 1 in 30 pediatric myocarditis cases and patients who require MCS have higher morbidity and mortality. ECMO is the most commonly used MCS modality in pediatric myocarditis but there is no significant difference in mortality based on MCS modality.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
